Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45
Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $47 to $45.
Stocks · News reference
Dyne Therapeutics To Present Preclinical Data On Four Candidates For Exon 53, 45, 44, And 55 Skipping In DMD At NMSG Meeting September 25; All Advancing Into IND-Enabling Studies
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading